We have collected information about Targeted Gene Delivery Of Bmpr2 Attenuates Pulmonary Hypertension for you. Follow the links to find out details on Targeted Gene Delivery Of Bmpr2 Attenuates Pulmonary Hypertension.
https://erj.ersjournals.com/content/39/2/329
Feb 01, 2012 · BMPR2 is predominantly expressed on pulmonary endothelium and has complex interactions with transforming growth factor (TGF)-β signalling mechanisms. Our objectives were to assess the effect on PAH of upregulating BMPR2 by targeted adenoviral BMPR2 gene delivery to the pulmonary vascular endothelium.Author: A. M. Reynolds, M. D. Holmes, M. D. Holmes, Sergei M. Danilov, P. N. Reynolds, P. N. Reynolds
https://www.researchgate.net/publication/51475337_Targeted_gene_delivery_of_BMPR2_attenuates_pulmonary_hypertension
Targeted gene delivery of BMPR2 attenuates pulmonary hypertension Article (PDF Available) in European Respiratory Journal 39(2):329-43 · July 2011 with 41 Reads How we measure 'reads'
https://erj.ersjournals.com/content/erj/39/2/329.full.pdf
Targeted gene delivery of BMPR2 attenuates pulmonary hypertension A.M. Reynolds*,#, M.D. Holmes*,#,", S.M. Danilov+,1 and P.N. Reynolds*,#," ABSTRACT: Pulmonary arterial hypertension (PAH) remains a fatal disease despite modern pharmacotherapy. Mutations in the gene for bone morphogenetic protein receptor type II (BMPR2)Author: A. M. Reynolds, M. D. Holmes, M. D. Holmes, Sergei M. Danilov, P. N. Reynolds, P. N. Reynolds
https://www.nature.com/articles/nm.3877
Jun 15, 2015 · BMP9 activates signaling through the BMPR-II receptor in endothelial cells and reverses established disease in three animal models of pulmonary hypertension, thus pointing to a potential new ...Author: Lu Long, Mark Leonard Ormiston, XuDong Yang, Mark Southwood, Stefan Andreas Gräf, Rajiv D Machado, M...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4922709/
Jul 01, 2016 · Loss of the growth-suppressive effects of bone morphogenetic protein (BMP) signaling has been demonstrated to promote pulmonary arterial endothelial cell dysfunction and induce pulmonary arterial smooth muscle cell (PASMC) proliferation, leading to the development of pulmonary arterial hypertension (PAH).Author: Alexander M.K. Rothman, Nadine D. Arnold, Josephine A. Pickworth, James Iremonger, Loredana Ciuclan,...
https://www.researchgate.net/publication/31957811_811_ACE-Targeted_eNOS_and_BMPR2_Gene_Therapy_Attenuates_Pulmonary_Hypertension_in_a_Chronic_Hypoxia_Rat_Model
ACE-Targeted eNOS and BMPR2 Gene Therapy Attenuates Pulmonary Hypertension in a Chronic Hypoxia Rat Model ... that BMPR2 gene delivery attenuated the …
http://core.ac.uk/display/12793062
BMPR2 is predominantly expressed on pulmonary endothelium and has complex interactions with transforming growth factor (TGF)-b signalling mechanisms. Our objectives were to assess the effect on PAH of upregulating BMPR2 by targeted adenoviral BMPR2 gene …
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3726153/
Aug 01, 2013 · Furthermore, patients with a BMPR2 mutation have worse pulmonary vascular remodeling . The importance of BMPR2 dysfunction in PAH is supported by studies in transgenic mice. Mice with deletion of BMPR2 in ECs develop PAH, as do mice expressing a dominant-negative Bmpr2 gene after birth in vascular SMCs .Author: Edda Spiekerkoetter, Xuefei Tian, Jie Cai, Rachel K. Hopper, Deepti Sudheendra, Caiyun G. Li, Nesrin...
https://www.dovepress.com/paeoniflorin-ameliorates-chronic-hypoxiasu5416-induced-pulmonary-arter-peer-reviewed-fulltext-article-DDDT
BMPR2 and its related signaling pathway have been recognized as a key regulator of pulmonary vascular homeostasis, as an estimated 80% of familial and 20% of idiopathic PAH patients carrying a heterozygous BMPR2 mutation. 28,29 BMPR2 gene mutations have also been found in patients with pulmonary hypertension caused by other factors (congenital ...Author: Min Yu, Liyao Peng, Ping Liu, Mingxia Yang, Hong Zhou, Yirui Ding, Jingjing Wang, Wen Huang, Qi Tan,...
https://onlinelibrary.wiley.com/doi/full/10.1111/resp.13552
INTRODUCTION. Pulmonary arterial hypertension (PAH) is a devastating disease and despite available therapeutics, median survival remains at 3–5 years after diagnosis. 1 The disease is characterized by increased pulmonary resistance due to vascular remodelling. Mutations in the bone morphogenetic protein receptor type 2 (BMPR2), leading to reduced receptor expression, are strongly associated ...Author: Rebecca L. Harper, Rebecca L. Harper, Suzanne Maiolo, Suzanne Maiolo, Rebekah J. Ward, Jemma Seyfang...
Searching for Targeted Gene Delivery Of Bmpr2 Attenuates Pulmonary Hypertension?
You can just click the links above. The data is collected for you.
